Arrowhead Pharmaceuticals Says Phase 1/2a Interim Single-Dose Data For ARO-DIMER-PA Showed Mean Maximal Reductions Of 54% In Bad Cholesterol, 73% In Triglycerides; No Drug-Related Serious Adverse Events
Share
Why It Matters
Arrowhead tested a new medicine that lowered bad cholesterol and triglycerides in early tests. No serious safety problems showed up, which is a good early sign for the drug.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.